Kardigan priced an upsized biopharma IPO to raise about $400 million gross, positioning three mid-stage cardiovascular programs focused on addressing root causes of heart disease. The company increased the offering to 25 million shares at $16 per share, at the top of its range, and framed the proceeds as support for key data readouts in 2027 that could set up Phase 3 testing. The debut highlights continued investor appetite for cardiovascular-risk programs with defined clinical milestones and a path to later-stage trials.